Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CFO Asif Ali sold 24,903 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the transaction, the chief financial officer now directly owns 62,821 shares of the company’s stock, valued at approximately $3,689,477.33. The trade was a 28.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Protagonist Therapeutics Stock Down 0.2 %
Shares of PTGX opened at $54.78 on Friday. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60. The company has a market capitalization of $3.36 billion, a PE ratio of 20.59 and a beta of 2.34. The stock has a fifty day simple moving average of $39.63 and a two-hundred day simple moving average of $42.24.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $2.07. The business had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. As a group, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Protagonist Therapeutics
Analysts Set New Price Targets
PTGX has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price on shares of Protagonist Therapeutics in a research note on Monday, March 10th. BMO Capital Markets increased their price objective on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. BTIG Research set a $73.00 price objective on Protagonist Therapeutics in a research note on Monday, March 3rd. JPMorgan Chase & Co. increased their price objective on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Finally, Wedbush reissued an “outperform” rating on shares of Protagonist Therapeutics in a research note on Tuesday. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.22.
Read Our Latest Research Report on PTGX
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Recommended Stories
- Five stocks we like better than Protagonist Therapeutics
- ESG Stocks, What Investors Should Know
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How is Compound Interest Calculated?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.